NASD · Healthcare · Biotechnology · USA
Ardelyx Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Ardelyx is a biopharmaceutical company that commercializes and develops medicines based on tenapanor, a sodium/hydrogen exchanger inhibitor. The company markets IBSRELA to treat adults with irritable bowel syndrome accompanied by constipation, and XPHOZAH to address elevated phosphorus levels in dialysis patients with chronic kidney disease. Ardelyx also develops a next-generation NHE3 inhibitor for multiple therapeutic uses.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Ardelyx Inc stock.
Undervalued: intrinsic value $7.21 per share, market price $3.18, margin of safety 55.9% (as of 2026-11-17).
A 4.2x revenue multiple, discounted for its losses, values the shares at $7.21; the price of $3.18 is 56% below that value.
17 more funds hold it; the full list is part of the paid plan.
3 more in this industry show a wider margin of safety.
ARDX is undervalued (as of the 2026-11-17 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $7.21; the price of $3.18 is 56% below that value.
$7.21 per share (as of the 2026-11-17 close), against a market price of $3.18. That is a margin of safety of 55.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.